What is Graphite Bio Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Graphite Bio's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Graphite Bio's Operating Income for the
three
months ended in Dec. 2023 was $ -14.60 Mil. Graphite Bio's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate Graphite Bio's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Graphite Bio Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio (NAS:GRPH) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Graphite Bio's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-14.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.08 Mil.
Graphite Bio's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Graphite Bio's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Graphite Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.
Graphite Bio (Graphite Bio) Business Description
Traded in Other Exchanges
N/A
Address
201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Executives
| Kimberlee C Drapkin |
director |
PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Ecor1 Capital, Llc |
10 percent owner |
357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
| Samsara Biocapital, L.p. |
10 percent owner |
628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
| Phil Gutry |
officer: CHIEF BUSINESS OFFICER |
400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
| Alethia Young |
officer: Chief Financial Officer |
C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
| Versant Ventures Vi Gp, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Matthew Porteus |
director |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| Katherine V Stultz |
officer: CHIEF OPERATING OFFICER |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| Abraham Bassan |
director |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| L.p. 436, |
10 percent owner |
628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
| Versant Vantage Ii Gp, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii Gp-gp, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Rizzuto Carlo |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Smital Shah |
director |
C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Graphite Bio (Graphite Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 